Compare ALCO & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALCO | ACHV |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.7M | 239.0M |
| IPO Year | N/A | N/A |
| Metric | ALCO | ACHV |
|---|---|---|
| Price | $39.12 | $5.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 24.9K | ★ 660.3K |
| Earning Date | 02-11-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $44,066,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.02 | $1.84 |
| 52 Week High | $39.46 | $6.03 |
| Indicator | ALCO | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 68.42 | 69.73 |
| Support Level | $34.64 | $5.30 |
| Resistance Level | $37.28 | $5.72 |
| Average True Range (ATR) | 0.88 | 0.34 |
| MACD | 0.26 | 0.08 |
| Stochastic Oscillator | 100.00 | 86.38 |
Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in the cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.